Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.41 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.41 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11289917 | 0.86 | CYP2D6 (0.46) | CNR2MAPTNR1H2NR1H3MEN1 | |
| SCHEMBL18234116 | 0.85 | CTNNB1 (0.44) | CTNNB1WNT3AAHRCNR2NR1H2 | |
| SCHEMBL7075474 | 0.79 | EIF4A1 (0.49) | MAPTNR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL8553165 | 0.79 | CYP2D6 (0.46) | MAPTNR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL10965843 | 0.79 | KMT2A (0.47) | AHRMAPTGRM4MEN1ALDH1A1 | |
| SCHEMBL9667242 | 0.77 | CTNNB1 (0.47) | CTNNB1WNT3ACNR2NR1H2NR1H3 | |
| SCHEMBL1124157 | 0.76 | NR1H2 (0.52) | CTNNB1WNT3ACNR2NR1H2NR1H3 | |
| SCHEMBL8556340 | 0.76 | KCNH2 (0.45) | MAPTNR1H2NR1H3MEN1ALDH1A1 | |
| SCHEMBL7221372 | 0.76 | CYP2D6 (0.46) | MAPTNR1H2NR1H3MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10668868 | 0.75 | CTNNB1 (0.67) | CTNNB1WNT3ACNR2GRM4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233481-A1 | Method for making mefloquine | Cilag Ltd. (CH) | 2010-09-29 | — | — | EP | claimed |
| EP-0092185-B1 | MEFLOQUINE-HYDROCHLORIDE AND PROCESS FOR ITS HIGH PURITY PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-04-20 | — | — | EP | claimed |
| US-4507482-A | TREATMENT WITH ALCOHOLS AND WATER | HOFFMANN-LA ROCHE INC. (US) | 1985-03-26 | — | — | US | claimed |
| EP-0092185-A2 | Mefloquine-hydrochloride and process for its high purity preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-10-26 | — | — | EP | claimed |
| EP-0026894-B1 | PROCESS FOR THE PREPARATION OF ERYTHRO-ALPHA-2-PIPERIDYL-2,8-BIS (TRIFLUOROMETHYL)-4-QUINOLINE METHANOL | BASF Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | claimed |
| EP-0026894-A1 | Process for the preparation of erythro-alpha-2-piperidyl-2,8-bis (trifluoromethyl)-4-quinoline methanol | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | claimed |
| US-20200197480-A1 | COMBINATION COMPRISING A PARTICULAR POLYMYXIN | HELPERBY THERAPEUTICS LTD (GB) | 2020-06-25 | — | — | US | disclosed |
| EP-2233481-A1 | Method for making mefloquine | Cilag Ltd. (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233481-A1 | Method for making mefloquine | Cilag Ltd. (CH) | 2010-09-29 | — | — | EP | disclosed |
| CN-1250540-C | Improved single-reactor synthesis of [2,8-di(trifluoromethyl)-4-quinolyl]-2-pyridyl methyl ketone and methylfluoro quine | NAT PHARMACEUTICAL EDUCATION A (IN) | 2006-04-12 | — | — | CN | disclosed |
| US-6664397-B1 | Administering to subject effective dose of (+)-mefloquine or pharmaceutically acceptable salt thereof substantially free of (-)-enantiomer; reduced side effects | VERNALIS RESEARCH LIMITED (GB) | 2003-12-16 | — | — | US | disclosed |
| US-6500955-B1 | CONDENSING A HALO- QUINOLINE WITH AN ALPHA-PICOLYL DERIVATIVES IN THE PRESENCE OF A SOLVENT AND A PHASE TRANSFER CATALYST AT -10 TO 90 DEGREE C. TO FORM (2,8-BIS (TRIFLUOROMETHYL)-4-QUINOLINYL)-2-PYRIDINYLMETHANONE | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) | 2002-12-31 | — | — | US | disclosed |
| US-6500955-B1 | CONDENSING A HALO- QUINOLINE WITH AN ALPHA-PICOLYL DERIVATIVES IN THE PRESENCE OF A SOLVENT AND A PHASE TRANSFER CATALYST AT -10 TO 90 DEGREE C. TO FORM (2,8-BIS (TRIFLUOROMETHYL)-4-QUINOLINYL)-2-PYRIDINYLMETHANONE | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) | 2002-12-31 | — | — | US | disclosed |
| US-4507482-A | TREATMENT WITH ALCOHOLS AND WATER | HOFFMANN-LA ROCHE INC. (US) | 1985-03-26 | — | — | US | disclosed |
| EP-0092185-A2 | Mefloquine-hydrochloride and process for its high purity preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-10-26 | — | — | EP | disclosed |
| EP-0026894-B1 | PROCESS FOR THE PREPARATION OF ERYTHRO-ALPHA-2-PIPERIDYL-2,8-BIS (TRIFLUOROMETHYL)-4-QUINOLINE METHANOL | BASF Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | disclosed |
| US-4327215-A | Preparation of erythio-αpiperid-2-yl-2,8-bis-trifluoro-methyl)-quinolin-4-yl-methanol | BASF AKTIENGESELLSCHAFT (DE) | 1982-04-27 | — | — | US | disclosed |
| EP-0049776-A2 | 4-Quinoline methane derivatives, their preparation and their use in the preparation of substances with a pharmacological activity | BASF Aktiengesellschaft (DE) | 1982-04-21 | — | — | EP | disclosed |
| EP-0026894-A1 | Process for the preparation of erythro-alpha-2-piperidyl-2,8-bis (trifluoromethyl)-4-quinoline methanol | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | disclosed |
| EP-0026894-A1 | Process for the preparation of erythro-alpha-2-piperidyl-2,8-bis (trifluoromethyl)-4-quinoline methanol | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197480-A1 | COMBINATION COMPRISING A PARTICULAR POLYMYXIN | VIP, TLR5, TLR4 | CTNNB1 4048/4885WNT3A 4444/4885AHR 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.